← IQVIA overview

IQVIA vs Tempus AI, Inc. Class A Common Stock: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

IQVIA Holdings Inc (IQV)

Q3 2026
▲3▼1

IQVIA Surges on Strong Q2, AI Push, and Buybacks

  • Q2 Beat and Guidance Raise IQVIA beat Q2 2026 estimates with revenue up 8.7% and EPS of $3.15, raised full-year guidance, and posted record bookings of $3.15B (up 19%) plus a $34.2B backlog. Shares jumped.

    This is the primary new event that drove the stock higher during the period.

  • AI Platforms and Gene Therapy Partnership New AI platforms aim to cut trial delays by up to two years, and a Medera partnership expands gene therapy reach. These initiatives position IQVIA for future growth and efficiency.

    These new strategic moves support the bullish narrative and future earnings potential.

  • Buybacks and Attractive Valuation The company executed $950M in buybacks, and the stock remains cheap at 16.2x forward earnings. Shares have rallied 42% in three months, aided by these repurchases.

    Buybacks and low valuation attracted investors and contributed to the price rally.

  • Debt Refinancing Raises Interest Costs IQVIA priced $2B in 6.375% senior notes to refinance 5% debt, adding roughly $27.5M in annual interest expense—a modest but real headwind to future profits. Also, the rally means shares are no longer inexpensive.

    This is a counterweight that could pressure future earnings and limit further upside.

August 2026
▲3▼1

IQVIA Surges on Strong Q2, AI Push, and Buybacks

  • Q2 Beat and Guidance Raise IQVIA beat Q2 2026 estimates with revenue up 8.7% and EPS of $3.15, raised full-year guidance, and posted record bookings of $3.15B (up 19%) plus a $34.2B backlog. Shares jumped.

    This is the primary new event that drove the stock higher during the period.

  • AI Platforms and Gene Therapy Partnership New AI platforms aim to cut trial delays by up to two years, and a Medera partnership expands gene therapy reach. These initiatives position IQVIA for future growth and efficiency.

    These new strategic moves support the bullish narrative and future earnings potential.

  • Buybacks and Attractive Valuation The company executed $950M in buybacks, and the stock remains cheap at 16.2x forward earnings. Shares have rallied 42% in three months, aided by these repurchases.

    Buybacks and low valuation attracted investors and contributed to the price rally.

  • Debt Refinancing Raises Interest Costs IQVIA priced $2B in 6.375% senior notes to refinance 5% debt, adding roughly $27.5M in annual interest expense—a modest but real headwind to future profits. Also, the rally means shares are no longer inexpensive.

    This is a counterweight that could pressure future earnings and limit further upside.

Latest
▲3▼1

IQVIA's record bookings, AI launches, and cheap valuation drive the stock

  • Record bookings and raised guidance IQVIA's second-quarter results beat expectations, with adjusted earnings up 12.1% and revenue up 8.7%. Crucially, new clinical bookings jumped 19% to $3.2 billion, a record, and the company raised its full-year revenue outlook. Strong bookings signal future growth, which supports a higher stock price.

    This is the core fundamental driver: accelerating demand and raised guidance directly boost investor confidence and the stock's value.

  • AI products speed up clinical trials IQVIA launched two AI-powered platforms: Predictive Clinical Development and Life Science Models. These tools aim to cut trial delays by up to two years and improve prediction accuracy. If adopted, they could win more business and make IQVIA's services more valuable, pushing the stock up over time.

    New AI products are a key growth catalyst, showing innovation that can expand IQVIA's market and margins.

  • Cheap valuation and buybacks IQVIA trades at a forward P/E of 16.2, much lower than peers like Penumbra, and has a Value grade of B. The company also bought back $398 million of shares in Q2, reducing the share count. A low valuation plus buybacks can attract investors and lift the stock.

    Valuation and capital returns are direct price drivers, making IQVIA look attractive relative to peers.

  • Higher interest costs from new debt IQVIA priced $2 billion in senior notes at 6.375% to refinance older 5% debt. This raises annual interest expense by about $27.5 million, slightly reducing future profits. While manageable, it's a headwind that could weigh on the stock.

    This is the main counterweight: increased debt costs pressure earnings, balancing the positive drivers.

▲4

IQVIA beats Q2, raises 2026 outlook on record bookings

  • Q2 beat and raised 2026 guidance IQVIA reported Q2 revenue of $4.37 billion (up 8.7%) and earnings of $3.15 per share, beating estimates. Management raised full-year 2026 revenue and profit guidance, pushing shares up 5% after hours and nearly 14% the next day. This directly lifts the stock because future profits are now expected to be higher.

    The earnings beat and guidance raise are the core new event that moved the stock this period.

  • Record $3.15B bookings and $34.2B backlog IQVIA's R&D Solutions unit signed a record $3.15 billion in new contracts in Q2, up 19% from a year ago. Its total contracted backlog hit a record $34.2 billion, with $9.2 billion expected to convert to revenue within 12 months. This signals strong future demand and supports the stock.

    Record bookings and backlog are new, concrete evidence of future revenue growth that investors care about.

  • Medera collaboration expands gene therapy reach IQVIA announced a partnership with Medera to combine its clinical trial and commercialization network with Medera's cardiac gene therapy and human-based drug discovery platforms. This expands IQVIA's presence in cell and gene therapy, a high-growth area, and supports its long-term R&D pipeline.

    This is a new strategic partnership that broadens IQVIA's technology and service offerings.

  • Stock up 42% in three months on strong results IQVIA shares have rallied 41.5% over the past three months, far outpacing the industry and the S&P 500. The run reflects the strong bookings, raised guidance, and $950 million of share buybacks in the first half of 2026. Momentum can attract more buyers, but also means the stock is no longer cheap.

    This summarizes the market's reaction to the new fundamentals and highlights the strong momentum, while noting valuation risk.

Tempus AI, Inc. Class A Common Stock (TEM)

Q3 2026
▲3▼1

Tempus AI swings to profit, buys Personalis, wins trial and FDA clearances

  • Q2 profit and raised guidance Tempus AI reported Q2 2026 net income of $5.64 million, swinging to a profit, and raised full-year revenue guidance to $1.60–$1.61 billion. This shows the company is growing and becoming more financially stable.

    Profitability and raised guidance are key positive financial developments that directly affect investor confidence and stock price.

  • Personalis acquisition and trial win Tempus agreed to buy Personalis for $1.5 billion to add minimal residual disease testing, and a phase 3 mRNA melanoma trial win sent shares up 39.5%. These expand its cancer testing and boost its technology.

    The acquisition and trial success are major strategic moves that drive growth and market excitement.

  • FDA clearances and partnership expansion Tempus won FDA clearance for two AI-ECG cardiac products and expanded a multi-year partnership with Moderna and Merck. These open new markets and strengthen its AI healthcare offerings.

    Regulatory approvals and partnerships are concrete milestones that validate the company's technology and drive future revenue.

  • Legal probes and insider stock sale Law firms are investigating whether Tempus's existing Personalis stake created conflicts of interest, and its legal chief sold $1.5 million in stock (tax withholding). These keep deal-related uncertainty alive.

    Legal scrutiny and insider selling can undermine investor trust and create overhang on the stock.

August 2026
▲3

Tempus wins FDA clearances, expands Moderna/Merck deal, Personalis buyout nears close

  • FDA clears two more AI heart tools Tempus won FDA clearance for two AI-ECG cardiac products, ECG-MR and ECG-PH, adding to its cleared heart lineup. Each new cleared product opens another billing stream and shows regulators keep accepting its AI, which supports the growth story behind the stock.

    New regulatory wins expand Tempus's commercial product pipeline and revenue potential.

  • Moderna and Merck expand Tempus partnership Tempus signed an expanded multi-year deal with Moderna and Merck to collect tissue and blood and run sequencing for their personalized mRNA cancer therapy. It deepens ties to major drugmakers and adds recurring service revenue, reinforcing demand for Tempus's testing and data.

    New commercial collaboration with major pharma partners directly boosts Tempus's service demand.

  • Personalis takeover looks set to close BTIG downgraded Personalis to Neutral, saying Tempus is highly likely to close its $1.5 billion acquisition at the agreed $16.25 per share, with no higher bidder expected. Removing deal uncertainty lets investors focus on the combined cancer-testing business.

    Reduced uncertainty around a major acquisition is a positive catalyst for Tempus shares.

  • Legal probes and insider sale add noise Law firms investigated whether Tempus's existing stake in Personalis created conflicts in the sale, and its legal chief sold $1.5 million of stock. The sale was just tax withholding, not a warning, but the probes keep deal-related uncertainty alive.

    These are the main counterweights to the positive deal and product news this period.

Latest
▲3

Tempus wins FDA clearances, expands Moderna/Merck deal, Personalis buyout nears close

  • FDA clears two more AI heart tools Tempus won FDA clearance for two AI-ECG cardiac products, ECG-MR and ECG-PH, adding to its cleared heart lineup. Each new cleared product opens another billing stream and shows regulators keep accepting its AI, which supports the growth story behind the stock.

    New regulatory wins expand Tempus's commercial product pipeline and revenue potential.

  • Moderna and Merck expand Tempus partnership Tempus signed an expanded multi-year deal with Moderna and Merck to collect tissue and blood and run sequencing for their personalized mRNA cancer therapy. It deepens ties to major drugmakers and adds recurring service revenue, reinforcing demand for Tempus's testing and data.

    New commercial collaboration with major pharma partners directly boosts Tempus's service demand.

  • Personalis takeover looks set to close BTIG downgraded Personalis to Neutral, saying Tempus is highly likely to close its $1.5 billion acquisition at the agreed $16.25 per share, with no higher bidder expected. Removing deal uncertainty lets investors focus on the combined cancer-testing business.

    Reduced uncertainty around a major acquisition is a positive catalyst for Tempus shares.

  • Legal probes and insider sale add noise Law firms investigated whether Tempus's existing stake in Personalis created conflicts in the sale, and its legal chief sold $1.5 million of stock. The sale was just tax withholding, not a warning, but the probes keep deal-related uncertainty alive.

    These are the main counterweights to the positive deal and product news this period.

July 2026
▲4

Tempus swings to profit, raises outlook, expands cancer data reach

  • Q2 profit and raised 2026 revenue guidance Tempus reported Q2 2026 net income of $5.64 million, a swing from a $42.84 million loss a year earlier, and lifted full-year revenue guidance to $1.60–$1.61 billion. Turning profitable and raising the outlook supports the growth story and helps justify a higher stock price.

    This is the period's clearest fundamental shift, directly improving earnings and forward revenue expectations.

  • Personalis acquisition deepens cancer recurrence testing Tempus agreed to buy Personalis for $16.25 per share, a $1.5 billion enterprise value, adding minimal residual disease testing to its oncology platform. The deal expands its cancer genomics and data offerings, though the initial market reaction was slightly negative on cost concerns.

    The acquisition is a major strategic move that broadens Tempus's technology and data moat, affecting long-term growth.

  • mRNA melanoma trial win lifts oncology data demand A phase 3 trial showed a customized mRNA melanoma treatment improved recurrence-free survival, sending Tempus shares up 39.5%. The result highlights how Tempus's data and AI tools are embedded in cutting-edge oncology, potentially boosting demand for its data and testing services.

    This event directly drove a large price move and validates Tempus's role in advanced cancer research.

  • 100,000-genome dataset expands AI research platform Tempus launched an initiative to build a 100,000 whole-genome dataset linked to clinical outcomes, with a long-term goal of one million genomes. This expands its data platform for AI-driven research, strengthening its competitive position and future data revenue potential.

    The new dataset initiative is a fresh expansion of Tempus's core data asset, supporting long-term growth.

▲4

Tempus swings to profit, raises outlook, expands cancer data reach

  • Q2 profit and raised 2026 revenue guidance Tempus reported Q2 2026 net income of $5.64 million, a swing from a $42.84 million loss a year earlier, and lifted full-year revenue guidance to $1.60–$1.61 billion. Turning profitable and raising the outlook supports the growth story and helps justify a higher stock price.

    This is the period's clearest fundamental shift, directly improving earnings and forward revenue expectations.

  • Personalis acquisition deepens cancer recurrence testing Tempus agreed to buy Personalis for $16.25 per share, a $1.5 billion enterprise value, adding minimal residual disease testing to its oncology platform. The deal expands its cancer genomics and data offerings, though the initial market reaction was slightly negative on cost concerns.

    The acquisition is a major strategic move that broadens Tempus's technology and data moat, affecting long-term growth.

  • mRNA melanoma trial win lifts oncology data demand A phase 3 trial showed a customized mRNA melanoma treatment improved recurrence-free survival, sending Tempus shares up 39.5%. The result highlights how Tempus's data and AI tools are embedded in cutting-edge oncology, potentially boosting demand for its data and testing services.

    This event directly drove a large price move and validates Tempus's role in advanced cancer research.

  • 100,000-genome dataset expands AI research platform Tempus launched an initiative to build a 100,000 whole-genome dataset linked to clinical outcomes, with a long-term goal of one million genomes. This expands its data platform for AI-driven research, strengthening its competitive position and future data revenue potential.

    The new dataset initiative is a fresh expansion of Tempus's core data asset, supporting long-term growth.